ReviewCancers2020

Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis.

Koichi Ando et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.